Beigene (BGNE.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec8

UOB Securities Analysts Positive on BeiGene's Revenue Growth Potential

04:37

Dec7

Two Drugs of BeiGene Entered the Commercial Insurance Innovative Drugs Directory

03:19

Dec4

Brokers Adjust Ratings and Target Prices for Multiple Stocks

01:00

Nov24

BeiGene's Q3 Total Revenue Reached 1.4 Billion USD, Up 41% YoY

06:33

Nov17

BeiGene Adds Gene Editing Concept, Expanding Cell Therapy

08:28

Beyter Zhishen Reports Better-than-Expected Q3 2025 Earnings, Upgrading Full-Year Guidance

07:46

Schedules & Filings

Schedules

Filings

Jan2

Ticker Change(EST)

From 01.02 changed to ONC

Nov12

Earning Release(EST)

FY2024 Q3 Earning Release (USD) Revenue 1.048 B, Net Income -154.1 M, EPS -1.4681

Aug7

Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 929.17 M, Net Income -120.41 M, EPS -1.15

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More